Explorez tous les épisodes du podcast The Lancet Infectious Diseases in conversation with
| Titre | Date | Durée | |
|---|---|---|---|
| Jenny Clarke and Herve Semukunzi | 09 Mar 2026 | 00:19:56 | |
Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbreak in Rwanda’. They also discuss the reasons for the paucity of validated serological assays for mpox, particularly in outbreak regions where they are most urgently needed. Click here to read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00006-X/fulltext Continue this conversation on social! | |||
| Julia Moore Vogel and Danilo Buonsenso on long COVID | 19 Dec 2025 | 00:27:33 | |
Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clinical trials, and future research priorities. Continue this conversation on social! | |||
| Sofia Viegas and Stefan Niemann on emerging bedaquiline resistance in Mozambique | 10 Nov 2023 | 00:24:35 | |
Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberculosis. Continue this conversation on social! | |||
| Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections | 27 Sep 2022 | 00:17:01 | |
Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil. Continue this conversation on social! | |||
| Richard Maude on malaria chemoprophylaxis in Cambodia | 27 Sep 2022 | 00:12:44 | |
Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia. Continue this conversation on social! | |||
| Ben Cowling on COVID-19 vaccines in Hong Kong | 15 Jul 2022 | 00:20:58 | |
Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong. Continue this conversation on social! | |||
| Hugh Adler on monkeypox in the UK | 26 May 2022 | 00:18:17 | |
Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021. Continue this conversation on social! | |||
| Beate Kampmann, Karen Keddy, and Peter Ghazal on applying big data to childhood infectious diseases in LMICs | 14 Dec 2021 | 00:22:16 | |
Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhood infectious diseases in LMICs. Continue this conversation on social! | |||
| Laura Cooper and Sam Okiror on polio eradication in Africa | 12 Oct 2021 | 00:21:34 | |
A new article highlights how changing immunity profiles motivate the need for better responses to outbreaks of polio in Africa. Continue this conversation on social! | |||
| Paul Chapman on a hookworm vaccine | 19 Aug 2021 | 00:20:57 | |
Paul Chapman and colleagues presents the results of an innovative trial assessing the safety of vaccinating healthy volunteers with attenuated Necator americanus hookworm larvae. Continue this conversation on social! | |||
| Josep Llibre on preventing SARS-CoV-2 transmission at concerts | 27 May 2021 | 00:08:10 | |
Josep Llibre discusses a trial on the impact of same-day testing for SARS-CoV-2 infection before a concert on new COVID-19 cases in Barcelona, Spain. Continue this conversation on social! | |||
| Yap Boum on COVID-19 testing in low resource settings | 25 Mar 2021 | 00:11:21 | |
Yap Boum (MSF) discusses his study done in Cameroon, which developed a promising testing strategy for COVID-19 to optimise the available resources. Continue this conversation on social! | |||
| In Conversation with Steven Tong and Joshua Davis on adaptive platform trials | 23 Oct 2025 | 00:25:48 | |
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! | |||
| Anna Odone, Jesus Rodriguez-Manzano, and Alex Howard on artificial intelligence and infectious diseases | 16 Sep 2025 | 00:29:12 | |
Professor Ana Odone, Dr Jesus Rodriguez-Manzano, and Dr Alex Howard discuss their new Series of papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape and in actively shaping artificial intelligence integration into practice. Read the full Series here: Continue this conversation on social! | |||
| Catherine Liu and Joshua Hill on prevention and management of infections in people who are immunocompromised | 11 Aug 2025 | 00:18:27 | |
Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of infections and diagnostic and antimicrobial stewardship. Read the Series papers: Read the linked Comment: Continue this conversation on social! | |||
| Lilian Tina Minja and Norbert Heinrich on TB drug development | 09 Jul 2025 | 00:29:53 | |
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment. Read the trials: Continue this conversation on social! | |||
| Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile | 10 Jun 2025 | 00:15:27 | |
Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond. Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf Continue this conversation on social! | |||
| Jan Felix Drexler and Fernando Bozza on Oropouche virus | 14 Apr 2025 | 00:35:17 | |
Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implications for Oropouche virus and other arboviruses transmission, expansion, surveillance, and control. Read the full article: Continue this conversation on social! | |||
| Prasad Kulkarni on dengue monoclonal antibodies | 23 Feb 2024 | 00:18:53 | |
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development. Continue this conversation on social! | |||
| Oriol Mitjà on treatment of early syphilis in adults | 08 Jan 2024 | 00:15:25 | |
Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis. Continue this conversation on social! | |||